Cervical cancer, malignant (ICD10 C53)
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
61.3% |
68.5% |
66.2% |
68.5% |
||||||||
|
(unstandardized) |
(57.3-65.0%) |
(65.1-71.6%) |
(62.2-69.8%) |
(64.5-72.1%) |
||||||||
|
all 15-99 |
53.6% |
63.2% |
55.8% |
56.8% |
63.8% |
60.4% |
||||||
|
(age-standardized)# |
(43.4-63.8%) |
(54.3-71.3%) |
(45.6-66.2%) |
(47.1-66.6%) |
(58.8-69.3%) |
(57.7-63.2%) |
||||||
|
15-44 |
68.9% |
77.4% |
78.0% |
81.4% |
||||||||
|
(63.6-73.6%) |
(73.0-81.1%) |
(72.4-82.4%) |
(76.4-85.5%) |
|||||||||
|
45-54 |
63.6% |
66.0% |
62.8% |
62.2% |
||||||||
|
(55.4-70.7%) |
(58.7-72.3%) |
(55.5-69.3%) |
(53.9-69.3%) |
|||||||||
|
55-64 |
49.2% |
58.1% |
55.3% |
62.5% |
||||||||
|
(37.9-59.6%) |
(48.8-66.3%) |
(44.3-65.0%) |
(50.4-72.5%) |
|||||||||
|
65-74 |
40.9% |
62.7% |
39.8% |
38.6% |
||||||||
|
(28.7-53.0%) |
(50.1-73.5%) |
(25.4-54.3%) |
(24.8-52.6%) |
|||||||||
|
75-99 |
35.8% |
39.7% |
26.5% |
18.6% |
||||||||
|
(18.6-55.8%) |
(25.9-54.6%) |
(10.3-48.3%) |
(6.8-36.2%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x28000, 45-54 x17000, 55-64 x21000, 65-74 x20000, 75-99 x14000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|